Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.
作者信息
Smith M R, Hong F, Li H, Gordon L I, Gascoyne R D, Paietta E M, Advani R H, Forero-Torres A, Horning S J, Kahl B S
机构信息
Fox Chase Cancer Center, Philadelphia, PA, USA.
Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
出版信息
Leukemia. 2017 Feb;31(2):517-519. doi: 10.1038/leu.2016.305. Epub 2016 Oct 26.
Abstract
摘要
相似文献
1
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.采用简化R-CHOP方案序贯钇-伊布替尼单抗进行套细胞淋巴瘤初始治疗：ECOG-ACRIN 2期研究E1499的10年随访结果
Leukemia. 2017 Feb;31(2):517-519. doi: 10.1038/leu.2016.305. Epub 2016 Oct 26.
2
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?一线自体干细胞移植后90Y-伊布替尼-替曲膦巩固治疗晚期套细胞淋巴瘤：是时候向前迈进了吗？
Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8. doi: 10.1016/j.clml.2015.11.014. Epub 2015 Nov 21.
3
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松免疫化疗后再用钇-90 替伊莫单抗替曲昔单抗治疗未经治疗的套细胞淋巴瘤的 II 期研究：东部肿瘤协作组研究 E1499。
J Clin Oncol. 2012 Sep 1;30(25):3119-26. doi: 10.1200/JCO.2012.42.2444. Epub 2012 Jul 30.
4
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.利妥昔单抗联合短期化疗后序贯钇-90 替伊莫单抗作为滤泡性非霍奇金淋巴瘤患者的一线治疗：莎拉·坎农肿瘤研究联盟的 II 期试验
Clin Lymphoma Myeloma. 2009 Jun;9(3):223-8. doi: 10.3816/CLM.2009.n.044.
5
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松进行免疫化疗可显著提高反应率并延长至治疗失败时间，但对既往未治疗的套细胞淋巴瘤患者的长期预后无改善：德国低度淋巴瘤研究组（GLSG）一项前瞻性随机试验的结果
J Clin Oncol. 2005 Mar 20;23(9):1984-92. doi: 10.1200/JCO.2005.08.133. Epub 2005 Jan 24.
6
Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.一线利妥昔单抗、环磷酰胺、阿霉素和泼尼松联合长春新碱（R-CHOP）或硼替佐米（VR-CAP）用于不适合移植的套细胞淋巴瘤（MCL）患者的3期研究。
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):9-11.
7
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.短疗程R-CHOP方案序贯（90）钇-伊布替尼单抗治疗既往未治疗的高危老年弥漫性大B细胞淋巴瘤患者：7年长期结果
Blood Cancer J. 2016 May 13;6(5):e425. doi: 10.1038/bcj.2016.29.
8
Mantle-cell lymphoma in the elderly: is it time to CHOP and change?老年套细胞淋巴瘤：是时候改变CHOP方案了吗？
Leuk Lymphoma. 2012 Oct;53(10):1855-6. doi: 10.3109/10428194.2012.695361. Epub 2012 Jun 13.
9
Treatment of older patients with mantle-cell lymphoma.治疗老年套细胞淋巴瘤患者。
N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.
10
Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.（90）钇替伊莫单抗替昔妥珠单抗（泽瓦林®）用于弥漫性大 B 细胞淋巴瘤高危患者缓解后治疗的临床结果。
Ann Hematol. 2011 Sep;90(9):1075-82. doi: 10.1007/s00277-011-1191-6. Epub 2011 Feb 19.
引用本文的文献
1
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.套细胞淋巴瘤采用苯达莫司汀-利妥昔单抗±硼替佐米诱导和利妥昔单抗±来那度胺维持治疗的随机研究。
Blood. 2024 Sep 5;144(10):1083-1092. doi: 10.1182/blood.2024023962.
2
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.异基因造血干细胞移植联合氟达拉滨和马法兰治疗高危 B 细胞非霍奇金淋巴瘤的 II 期临床试验结果。
Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23.
3
Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials.肿瘤学中的放射免疫疗法：过去十年临床试验综述
Cancers (Basel). 2021 Nov 7;13(21):5570. doi: 10.3390/cancers13215570.
4
Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.放射性免疫疗法治疗套细胞淋巴瘤：国际 RIT 注册中心 90 例患者的 5 年随访结果。
Ann Hematol. 2020 May;99(5):1073-1079. doi: 10.1007/s00277-020-03956-0. Epub 2020 Mar 3.
5
Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.针对套细胞淋巴瘤的风险定制治疗策略。
Curr Oncol Rep. 2018 Aug 22;20(10):79. doi: 10.1007/s11912-018-0728-4.
6
Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.年轻体健的套细胞淋巴瘤患者的首要治疗选择：一线治疗策略。
J Exp Clin Cancer Res. 2018 Jul 13;37(1):150. doi: 10.1186/s13046-018-0800-9.
7
Frontline Treatment for Older Patients with Mantle Cell Lymphoma.老年套细胞淋巴瘤患者的一线治疗。
Oncologist. 2018 Nov;23(11):1337-1348. doi: 10.1634/theoncologist.2017-0470. Epub 2018 Jun 12.
本文引用的文献
1
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.套细胞淋巴瘤临床试验开发建议
J Natl Cancer Inst. 2016 Dec 31;109(1). doi: 10.1093/jnci/djw263. Print 2017 Jan.
2
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.利妥昔单抗联合强化环磷酰胺、长春新碱、阿霉素和地塞米松（hyper-CVAD）与甲氨蝶呤/阿糖胞苷（MTX/Ara-C）交替用于新诊断的套细胞淋巴瘤患者：来自MD安德森癌症中心一项II期研究的15年随访
Br J Haematol. 2016 Jan;172(1):80-8. doi: 10.1111/bjh.13796. Epub 2015 Dec 9.
3
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.硼替佐米为基础的治疗新诊断的套细胞淋巴瘤。
N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.
4
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.在欧洲套细胞淋巴瘤网络的随机试验中确认套细胞淋巴瘤国际预后指数。
J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466. Epub 2014 Mar 31.
5
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.伊布替尼治疗复发或难治性套细胞淋巴瘤中的 BTK。
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
6
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.利妥昔单抗-高剂量环磷酰胺、阿霉素、长春新碱和地塞米松（hyperCVAD）联合利妥昔单抗-甲氨蝶呤-阿糖胞苷一线治疗后，继以 90Y-替伊莫单抗-奥法木单抗巩固治疗套细胞淋巴瘤患者。GELTAMO 组的一项多中心、2 期试验的结果。
Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10.
7
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.一项多中心 II 期临床试验，研究 HyperCVAD MTX/Ara-C 和利妥昔单抗在未经治疗的套细胞淋巴瘤患者中的疗效；SWOG0213。
Ann Oncol. 2013 Jun;24(6):1587-93. doi: 10.1093/annonc/mdt070. Epub 2013 Mar 15.
8
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.苯达莫司汀联合利妥昔单抗与 CHOP 联合利妥昔单抗作为惰性和套细胞淋巴瘤患者一线治疗的比较：一项开放标签、多中心、随机、3 期非劣效性临床试验。
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
9
Treatment of older patients with mantle-cell lymphoma.治疗老年套细胞淋巴瘤患者。
N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.
10
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松免疫化疗后再用钇-90 替伊莫单抗替曲昔单抗治疗未经治疗的套细胞淋巴瘤的 II 期研究：东部肿瘤协作组研究 E1499。
J Clin Oncol. 2012 Sep 1;30(25):3119-26. doi: 10.1200/JCO.2012.42.2444. Epub 2012 Jul 30.
Zotero 插件